Treatments for nail psoriasis: A systematic review by the GRAPPA nail psoriasis work group

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2306-2314

  Armstrong, April W ^a,b   Tuong, William ^b   Love, Thorvardur J ^c   Carneiro, Sueli ^d   Grynszpan, Rachel ^d   Lee, Steve S ^e   Kavanaugh, Arthur ^f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ICELAND   (Iceland)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Effectiveness; Nail psoriasis; Psoriasis efficacy; Treatment therapy

Indexed keywords

ADALIMUMAB; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BRIAKINUMAB; CALCIPOTRIOL; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; TACROLIMUS; TAZAROTENE; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT;

CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; NAIL PSORIASIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PULSED DYE LASER; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; LOW LEVEL LASER THERAPY; MALE; MULTIMODALITY CANCER THERAPY; NAIL DISEASES; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROCEDURES; PUVA; SEVERITY OF ILLNESS INDEX; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LASER THERAPY; MALE; NAIL DISEASES; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84923252870     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140881     Document Type: Review

References (42)

1. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006; 33:1452-6.
2. Rigopoulos D, Gregoriou S, Daniel CR III, Belyayeva H, Larios G, Verra P, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218:338-41.
3. Tzung TY, Chen CY, Yang C.Y., Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88:279-80.
4. De Simone C, Maiorino A, Tassone F., D'Agostino M, Caldarola G. Tacrolimus 0.1% ointment in nail psoriasis: Arandomized controlled open-label study. J Eur Acad Dermatol Venereol 2013; 27:1003-6.
5. Fischer-Levancini C, Sanchez-Regana M, Llambi F., Collgros H, Exposito-Serrano V, Umbert-Millet P. Nail psoriasis: Treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr 2012; 103:725-8.
6. Goldust M, Raghifar R. Clinical trial study in the treatment of nail psoriasis with pulsed dye laser. J Cosmet Laser Ther 2013 Oct 16 [Epub ahead of print].
7. Treewittayapoom C, Singvahanont P, Chanprapaph K., Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: Arandomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol 2012; 66:807-12.
8. Gumusel M, Özdemir M, Mevlitoglu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: A one-blind, randomized study. J Eur Acad Dermatol Venereol 2011; 25:1080-4.
9. Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernandez M, Umbert-Millet P. Nail psoriasis: A retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol 2011; 25:579-86.
10. Syuto T, Abe M, Ishibuchi H., Ishikawa O. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 2007; 17:248-9.
11. Karanikolas GN, Koukli EM, Katsalira A, Arida A., Petrou D, Komninou E, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: Results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011; 38:2466-74.
12. Kingsley GH, Kowalczyk A, Taylor H., Ibrahim F, Packham JC, McHugh N.J., et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012; 51:1368-77.
13. Reich K, Langley RG, Papp K.A., Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586-96.
14. Demirsoy EO, Kiran R, Salman S., Caglayan C, Akturk AS, Bayramgurler D, et al. Effectiveness of systemic treatment agents on psoriatic nails: A comparative study. J Drugs Dermatol 2013; 12:1039-43.
15. Tosti A, Ricotti C, Romanelli P., Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145:269-71.
16. Behrens F, Finkenwirth C, Pavelka K., Stolfa J, Sipek-Dolnicar A, Thaci D, et al. Leflunomide in psoriatic arthritis: Results from a large European prospective observational study. Arthritis Care Res 2013; 65:464-70.
17. Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice. J Dermatolog Treat 2012; 23:203-7.
18. Leonardi C, Langley RG, Papp K, Tyring S.K., Wasel N., Vender R, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: Efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147:429-36.
19. Rigopoulos D, Gregoriou S, Lazaridou E., Belyayeva E, Apalla Z, Makris M., et al. Treatment of nail psoriasis with adalimumab: An open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24:530-4.
20. Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Hoick P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69:394-9.
21. Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R117.
22. Ozmen I, Erbil AH, Koc E, Tunca M. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: An open-label, unblinded, comparative study. J Dermatol 2013; 40:755-6.
23. Saraceno R, Pietroleonardo L, Mazzotta A., Zangrilli A, Bianchi L, Chimenti S. TNF-alpha antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opin Biol Ther 2013; 13:469-73.
24. Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: A single-center, retrospective, comparative study. J Dermatolog Treat 2013; 24:162-8.
25. Mease PJ, Fleischmann R, Deodhar A.A., Wollenhaupt J., Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73:48-55.
26. Ortonne JP, Paul C, Berardesca E., Marino V, Gallo G, Brault Y., et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168:1080-7.
27. Luger TA, Barker J, Lambert J., Yang S, Robertson D, Foehl J., et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23:896-904.
28. Kavanaugh A, Mclnnes I, Mease P., Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976-86.
29. Kavanaugh A, van der Heijde D, Mclnnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012; 64:2504-17.
30. Fabroni C, Gori A, Troiano M., Prignano F, Lotti T. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol 2011; 25:549-53.
31. Torii H, Nakagawa H, Japanese Infliximab Study I. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38:321-34.
32. Reich K, Ortonne JP, Kerkmann U, Wang Y., Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS Trial. Dermatology 2010; 22:172-8.
33. Torii H, Nakagawa H, Japanese Infliximab Study I. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59:40-9.
34. Rich P, Griffiths CE, Reich K, Nestle F.O., Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58:224-31.
35. Rigopoulos D, Gregoriou S, Stratigos A., Larios G, Korfitis C, Papaioannou D., et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159:453-6.
36. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 2013; 24:96-100.
37. Rich P, Bourcier M, Sofen H., Fakharzadeh S, Wasfi Y, Wang Y., et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1. Br J Dermatol 2014; 170:398-407.
38. Vitiello M, Tosti A, Abuchar A., Zaiac M, Kerdel FA. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients. Int J Dermatol 2013; 52:358-62.
39. Igarashi A, Kato T, Kato M., Song M, Nakagawa H, Japanese Ustekinumab Study G. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39:242-52.
40. Rigopoulos D, Gregoriou S, Makris M., Ioannides D. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: An open prospective unblinded study. Dermatology 2011; 223:325-9.
41. Leonardi C, Matheson R, Zachariae C., Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190-9.
42. Huang YC, Chou CL, Chiang YY. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single-blind, intrapatient left-to-right controlled study. Lasers Surg Med 2013; 45:102-7.